Association Review
In brief
The association between SMAD3 (SMAD Family Member 3) and Soft Tissue Sarcoma is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
0
Compounds
1
Trials
163of 1,837 via SMAD3 compounds
Publications
0
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
1 source summary
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Soft Tissue Sarcoma
The disorder
7 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
Interventions
Therapeutics
1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
06
Human studies
Clinical trials
1,837 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
07
Provenance
References & sources
4 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access